Endo International Plc Class Action Lawsuit - ENDP

(i) Endo’s and/or its subsidiaries’ contributions to the opioid crisis (including, but not limited to, their opioid products’ disproportionately negative impact on New York and the fraud that Defendants perpetrated on the New York insurance market) were larger in scope than the Company had represented; (ii) part of that contribution to the crisis included Endo publishing and disseminating false information to health care providers regarding the risks and benefits of opioids; (iii) the foregoing, once revealed, was foreseeably likely to subject Endo and/or its subsidiaries to increased regulatory scrutiny and enforcement, as well as significant financial and/or reputational harm, particularly with respect to New York; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the ENDP class action lawsuit, you must have incurred a loss on shares of Endo purchased during the class period listed above.

If you suffered a loss in Endo during the relevant time frame or pursuant to the relevant offering(s), you have until August 18, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.